Pregled bibliografske jedinice broj: 1266003
Expert Consideration on Regulatory Aspects for Perinatal Derivatives in Clinical Settings
Expert Consideration on Regulatory Aspects for Perinatal Derivatives in Clinical Settings // Stem Cells Translational Medicine, 12 (2023), 5; 258-265 doi:10.1093/stcltm/szad017 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1266003 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Expert Consideration on Regulatory Aspects for
Perinatal Derivatives in Clinical Settings
Autori
Hofmann, Nicola ; Lafarge, Xavier ; Antica, Mariastefania ; Ferry, Nicolas ; Girandon, Lenart ; Gramignoli, Roberto ; Jurga, Marcin ; Kerdjoudj, Halima ; Navakauskiene, Ruta ; Schiavi, Jessica ; Shablii, Volodymyr ; Nicolás, Francisco J ; Gindraux, Florelle
Izvornik
Stem Cells Translational Medicine (2157-6564) 12
(2023), 5;
258-265
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
perinatal tissues ; placenta ; European regulation ; cell therapy ; ATMP.
Sažetak
Perinatal derivatives (PnD) are drawing growing interest among the scientific community as an unrestricted source of multipotent stem cells, secretome, and biological matrices. They are useful for the treatment of diseases that currently have limited or no effective therapeutic options, but they require the development of regenerative approaches. With this development, the question of regulation of donation, processing, and distribution has therefore become more important. Within the European Cooperation in Science and Technology (COST) community, we compiled a group of international experts on PnD technologies, who revised and compared existing EU national regulations. Notably, despite clear European directives, each EU Country has developed their own implementation and standard levels for cell- and tissue-based therapies. To enable extended applications of PnD treatments within the EU community and worldwide, harmonization is highly recommended. This paper aims to provide an overview of the various options available to introduce PnD into clinical practice. For this purpose, the different aspects resulting from (1) the type of PnD, (2) the amount of available data, (3) the degree of manipulation, and (4) the intended application and the process toward a possible commercialization will be presented. In the future, it will be important to find a balance between regulatory requirements and the best medical quality of the PnD product.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
HRZZ-IP-2020-02-2431 - Obnova timusa za preciznu medicinu u liječenju tumora i leukemija (THYMINNOVA) (Antica, Mariastefania, HRZZ - 2020-02) ( CroRIS)
--KK.01.1.1.01.0008 - Znanstveni centar izvrsnosti za reproduktivnu i regenerativnu medicinu – istraživanja novih platormi i potencijala (CERRM) (Ježek, Davor; Vukičević, Slobodan) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb
Profili:
Mariastefania Antica
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE